Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy

Research output: Contribution to journalArticle

Abstract

Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.

Original languageEnglish
Pages (from-to)2569-2578
Number of pages10
JournalFuture Oncology
Volume10
Issue number16
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Vomiting
Appointments and Schedules
Antiemetics
Drug Therapy
Dexamethasone
Odds Ratio
Ondansetron
Nausea
palonosetron

Keywords

  • CINV
  • dexamethasone
  • high-dose chemotherapy
  • nausea
  • vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. / Mirabile, Aurora; Celio, Luigi; Magni, Michele; Bonizzoni, Erminio; Gianni, Alessandro Massimo; Di Nicola, Massimo.

In: Future Oncology, Vol. 10, No. 16, 01.12.2014, p. 2569-2578.

Research output: Contribution to journalArticle

@article{1aae7ce4c4c84a69abcf7f16a873e5b3,
title = "Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy",
abstract = "Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81{\%} and 50{\%} of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.",
keywords = "CINV, dexamethasone, high-dose chemotherapy, nausea, vomiting",
author = "Aurora Mirabile and Luigi Celio and Michele Magni and Erminio Bonizzoni and Gianni, {Alessandro Massimo} and {Di Nicola}, Massimo",
year = "2014",
month = "12",
day = "1",
doi = "10.2217/fon.14.132",
language = "English",
volume = "10",
pages = "2569--2578",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy

AU - Mirabile, Aurora

AU - Celio, Luigi

AU - Magni, Michele

AU - Bonizzoni, Erminio

AU - Gianni, Alessandro Massimo

AU - Di Nicola, Massimo

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.

AB - Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.

KW - CINV

KW - dexamethasone

KW - high-dose chemotherapy

KW - nausea

KW - vomiting

UR - http://www.scopus.com/inward/record.url?scp=84910033052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910033052&partnerID=8YFLogxK

U2 - 10.2217/fon.14.132

DO - 10.2217/fon.14.132

M3 - Article

C2 - 24947121

AN - SCOPUS:84910033052

VL - 10

SP - 2569

EP - 2578

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 16

ER -